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Objectives This study sought to develop a novel approach to optimizing continuous-flow left ventricular assist device
(CF-LVAD) function and diagnosing device malfunctions.
Background In CF-LVAD patients, the dynamic interaction of device speed, left and right ventricular decompression, and valve
function can be assessed during an echocardiography-monitored speed ramp test.
Methods We devised a unique ramp test protocol to be routinely used at the time of discharge for speed optimization
and/or if device malfunction was suspected. The patient’s left ventricular end-diastolic dimension, frequency of
aortic valve opening, valvular insufficiency, blood pressure, and CF-LVAD parameters were recorded in incre-
ments of 400 rpm from 8,000 rpm to 12,000 rpm. The results of the speed designations were plotted, and lin-
ear function slopes for left ventricular end-diastolic dimension, pulsatility index, and power were calculated.
Results Fifty-two ramp tests for 39 patients were prospectively collected and analyzed. Twenty-eight ramp tests were
performed for speed optimization, and speed was changed in 17 (61%) with a mean absolute value adjustment
of 424  211 rpm. Seventeen patients had ramp tests performed for suspected device thrombosis, and
10 tests were suspicious for device thrombosis; these patients were then treated with intensified anticoagulation
and/or device exchange/emergent transplantation. Device thrombosis was confirmed in 8 of 10 cases at the
time of emergent device exchange or transplantation. All patients with device thrombosis, but none of the re-
maining patients had a left ventricular end-diastolic dimension slope 0.16.
Conclusions Ramp tests facilitate optimal speed changes and device malfunction detection and may be used to monitor the
effects of therapeutic interventions and need for surgical intervention in CF-LVAD patients. (J Am Coll Cardiol
2012;60:1764–75) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.052w
aContinuous-flow left ventricular assist devices (CF-
LVADs) are an important therapeutic option for patients
with advanced congestive heart failure (1–3). LVADs have
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accepted July 24, 2012.traditionally been implanted as a bridge to transplantation
(2,3), with average support times of 6 to 12 months.
However, left ventricular assist devices (LVADs) are in-
creasingly used for the purpose of destination therapy (1),
here support duration averages 2 to 4 years and is
pproaching a decade in individual patients. One-year
See page 1776
survival in patients awaiting transplantation while on
LVAD support has increased from 55% to 85% (4) and is
approaching 80% in destination therapy patients in the most
recent U.S. experience (5). Cumulative global experience with
the currently U.S. Food and Drug Administration–approved
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ifornia) exceeds 8,000 patient-years, and it has become clear
that management of the patient–device interface (e.g., speed
optimization and anticoagulation) is at the epicenter of further
improvement possibilities.
Currently, recommendations for device speed adjustment
include target measures of mean arterial pressure 65 mm Hg,
middle interventricular septum position, and intermittent
aortic valve (AV) opening while maintaining no more than
mild mitral regurgitation (MR) to ensure appropriate un-
loading of the left ventricle (6). Optimal speed settings may
reduce the frequency of several of the key complications
related to long-term LVAD support. The importance of
ensuring middle septal position for optimal right ventricular
function is now well established (6), but our understanding
of speed optimization continues to evolve beyond acute
hemodynamic effects. For example, we recently reported the
development of de novo aortic insufficiency (AI) in 25% of
patients remaining on CF-LVADs for at least 1 year (7).
Interestingly, AI occurred in the majority of patients (66%)
whose AVs remained closed during support, but rarely (8%)
in those whose AV opened regularly; a nearly identical
prevalence of AI and association with AV opening has been
reported by others (8,9). It is therefore conceivable, al-
though unproven, that proactively maintaining intermittent
opening of the AV during support may delay or prevent the
development of AI. Intermittent AV opening also results in
a more pulsatile flow pattern, and it has been hypothesized
that increased pulsatility may attenuate the development of
von Willebrand factor deficiency (10).
The dynamic assessment of device speed, left ventricular
decompression, and valvular function during an echocardio-
graphically monitored ramp study may not only allow device
speed optimization in individual patients, but abnormalities
in this interaction may also aid in the diagnosis of device
malfunction. Although the use of ramp studies for CF-
LVAD management is recommended in the literature, no
specific protocol has been reported or endorsed.
Ramp Test Protocol (for HeartMate II)Table 1 Ramp Test Protocol (for HeartMate II)
Speed, rpm PI Power Flow BP HR
8,000
8,400
8,800
9,200
9,600
10,000
10,400
10,800
11,200
11,600
12,000
Similar ramp test protocol was developed for the Heartware device.
AI  aortic insufficiency; AV  aortic valve; BP  blood pressure; HR  heart rate; LVEDD  left v
egurgitation; PI  pulsatility index; RVSP  right ventricular systolic pressure.In the current study, we aimed
to develop a systematic approach
to perform and analyze ramp
tests to optimize device function
and diagnose device malfunc-
tions, specifically device throm-
bosis, an uncommon but poten-
tially catastrophic complication
of CF-LVADs.
Methods
A prospective study of all ramp
tests performed at Columbia
University Medical Center–New
York Presbyterian Hospital from
June 1, 2011, until April 5, 2012,
was conducted. The Columbia University Institutional Re-
view Board approved this study and all patients signed
informed consent.
After devising a standardized ramp test protocol for the
HeartMate II (Table 1) in early 2011, ramp tests have been
performed at our institution routinely for speed optimiza-
tion or when device thrombosis is suspected. Protocol for
patients supported by the HeartWare device (HeartWare
International, Framingham, Massachusetts) is provided in
the Online Appendix.
With regard to speed optimization, we followed the
current recommendations to ensure middle interventricular
septum position, and intermittent AV opening while main-
taining no more than mild MR.
Device thrombosis was suspected clinically based on at
least 1 the following: 1) transient increases in pump power
(power spikes) 14 days after device implantation or
gradually increasing power requirements of at least 2 W;
2) lactate dehydrogenase (LDH) level 1,000 U/l or
persistently increasing LDH in repeated blood work in
conjunction with low haptoglobin and/or high plasma free
hemoglobin in the absence of other causes of hemolysis (our
Abbreviations
and Acronyms
AI  aortic insufficiency
AV  aortic valve
CF-LVAD  continuous-flow
left ventricular assist
device
LDH  lactate
dehydrogenase
LVAD  left ventricular
assist device
LVEDD  left ventricular
end-diastolic dimension
MR  mitral regurgitation
PI  pulsatility index
EDD LVESD AV Opening AI MR RVSPentricular end-diastolic diameter; LVESD  left ventricuLVlar end-systolic diameter; MR  mitral
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The LVAD Ramp Study October 30, 2012:1764–75outpatient LVAD follow-up protocol consists of routine
LDH level checks once per month; at Columbia University
Medical Center, the upper limit of normal for LDH is 221
IU/l); and the 3) development of left-sided heart failure
without apparent other causes such as severe AI.
The final diagnosis of device thrombosis required direct
visualization of a clot in the pump on device explantation
and/or disassembly by the manufacturer.
Ramp test protocol. First, baseline demographic data as
well as surgical history, current medications, and laboratory
parameters including anticoagulation, platelet count, and
LDH, bilirubin, haptoglobin, and plasma free hemoglobin
levels, where applicable, were collected (Fig. 1, Table 1).
Second, baseline parameters were reviewed to ensure
safety. 1) Appropriate anticoagulation (international nor-
malized ratio 1.8 or partial thromboplastin time 60 s)
as confirmed. If adequate anticoagulation was not dem-
nstrated, a routine ramp test for speed adjustment was
ostponed until therapeutic anticoagulation was reached. In
ases of suspected device thrombosis, heparin 60 U/kg was
iven intravenously, and the ramp test was subsequently
erformed. 2) Baseline transthoracic echocardiography was
erformed; if it revealed an intraventricular or aortic root
hrombus, the ramp study was not performed due to the
ossibility of thrombus dislodgment.
Third, baseline echocardiographic and device parameters
see the following for details) were recorded.
Figure 1 Consideration for the Ramp Test Algorithm
Algorithm for consideration of ramp tests based on anticoagulation studies and pr
Doppler in order to be eligible to start the ramp test. INR  international normaliz
TTE  transthoracic echocardiography.ulsatility index. Contraction of the left ventricle increases
he flow of blood into the pump. The magnitude of these flow
ulses is measured by the pump and averaged over a 15-s
nterval to produce the displayed pulsatility index (PI) value.
Suction events occur when the pump speed is set high
nough to cause partial collapse of the left ventricle resulting
n obstruction of the inflow cannula by adjacent myocar-
ium. When suction events occur, they automatically reduce
he speed to the low speed setting (typically set at 400 to 800
pm below the fixed speed setting).
Fourth, the LVAD back-up speed was set at 8,000 rpm
o allow the actual device speed to be set as low as 8,000 rpm
ithout causing low-flow speed alarms.
Fifth, the patient’s device speed was lowered to 8,000 rpm.
fter 2 min, transthoracic echocardiographic images were
btained, and the following parameters were recorded: left
entricular end-diastolic dimension (LVEDD), left ventricular
nd-systolic diameter, frequency of AV opening, degree of AI,
egree of MR, right ventricular systolic pressure, Doppler
lood pressure, and heart rate. In addition, the following pump
arameters were recorded: power, PI, and flow.
Specifically, transthoracic echocardiographic parameters
ere measured as follows (Fig. 2). 1) LVEDD and left
entricular end-systolic dimension were measured from the
arasternal long-axis view (Fig. 2A). 2) AV opening was
ssessed using M-mode over the AV in the parasternal
ong-axis view. At least 10 consecutive cardiac cycles were
eviewed, and the frequency of AV opening was recorded as
e of intracardiac thrombus. Blood pressure should be below 110 mm Hg by
o; IV  intravenous; LV  left ventricular; PTT  partial thromboplastin time;esenc
ed rati
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Visual estimation of the severity of AI and MR was
performed in the parasternal long-axis view using the color
Doppler imaging technique (Figs. 2C and 2D). For assess-
ment of AI and MR, the degree of regurgitation was graded
from 0 to 6 (0  none; 1  trace; 2  mild; 3  mild to
oderate; 4  moderate; 5  moderate to severe; 6 
severe). Taking into account that AI during CF-LVAD
Figure 2 Images for Obtaining Transthoracic Echocardiography
(A) Left ventricular end-diastolic dimension assessment in the parasternal long-ax
assessment by color Doppler imaging. (D) Mitral valve insufficiency assessment b
imaging. MAP  mean arterial pressure.support is generally both systolic and diastolic, AI wasdeemed significant if graded 3 (mild to moderate) or greater
(7). 4) Right ventricular systolic pressure was estimated
from peak tricuspid regurgitant velocity using modified
Bernoulli’s equation (Fig. 2E).
Next, the device speed was subsequently increased by 400
rpm at 2-min intervals with repeated acquisition of all
echocardiographic and device parameters at each speed step.
The 400-rpm increments continued from 8,000 to 12,000
meters
. (B) Aortic valve opening assessment by M-mode. (C) Aortic valve insufficiency
Doppler imaging. (E) Right ventricular systolic pressure assessment by DopplerPara
is view
y colorrpm. The ramp test was stopped if any suction events
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The LVAD Ramp Study October 30, 2012:1764–75occurred and/or if the LVEDD decreased to 3.0 cm. At
the test’s conclusion, the attending cardiologist reviewed the
recordings from the test while at the patient’s bedside.
Device speed was then set to allow intermittent AV opening
while maintaining Doppler blood pressure65 mm Hg and
avoiding more than mild MR.
Finally, the recordings of the ramp test parameter results
at the respective 11 speed points were plotted in Excel 2007
Figure 3 Graphs of Normal Example Versus Device Thrombosis
(A) LVEDD slope, PI slope, and power slope of a patient with normal device function. (B)
AV  aortic valve; LVAD  left ventricular assistive device; LVEDD  left ventricular end-disoftware (Microsoft Corp., Redmond, Washington). Linearfunction slopes for LVEDD, PI, and power were calculated
(Fig. 3A) using Excel software.
Statistical analysis. Data were collected using Excel 2007
software. All data were analyzed using R version 2.15.0.
Categorical variables were summarized by frequencies and
percentages and were analyzed using the Fisher exact test.
The Student t test for independent samples was used to
determine differences in normally distributed data. The
ple of LVEDD, PI, and Power
slope, PI slope, and power slope of a patient with device thrombosis.
dimension; PI  pulsatility index.Exam
LVEDD
astolicWilcoxon rank sum test was used to determine differences in
eft ven
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October 30, 2012:1764–75 The LVAD Ramp Studynon-normal distributions. Normality was assessed using the
Shapiro-Wilk normality test. Receiver-operating character-
istic curve analysis was done using the pROC package (11).
Baseline Characteristics and Results: Device Thrombosis PatientsNo Thrombosis Pat ents (n  29) Versus All Patients (n  39)Table 2 B selin Characteri tic and Resul s: Device ThromboNo Thrombosis Patients (n  29) Versus All Patients (
Confirmed Thrombosis
Patients
(n  8)
Age, yrs 53 20
Male 5 (62)
Race 2 (25) AA, 6 (75) other
Heart failure etiology, dilated
cardiomyopathy
4 (50)
Hypertension 3 (38)
Diabetes mellitus 3 (38)
Former smoker 5 (62)
IVS, cm 1.0 0.2
LVAD surgery combined with
Mitral valve repair 1 (13)
AV repair/closure 0 (0)
Tricuspid valve repair 1 (13)
PFO closure 1 (13)
Ramp test results
LVEDD slope 0.08 0.04
PI slope 0.16 0.04
Power slope 0.74 0.15
Speed for complete AV closure 11,100 1,146
LDH value 1,737 684
Low haptoglobin 7
High plasma-free hemoglobin 19.1 14.0
Length of follow-up, post-ramp test, days 171 111
Values are mean  SD, n (%), or mean. *Two patients, 1 with a gross bend relief disconnect and 1
all patient cohorts, but they were excluded in the confirmed device thrombosis versus no thrombo
AA  African American; IVS  interventricular septum; LDH  lactate dehydrogenase; LVAD  l
Table 1.
Summary of SpeedOpti izati n Ramp Tests (28 Tests)Table 3 ummary of SpeedOptimization Ramp Tests (28 Tests)
Parameter
Set Clinical Speed
Pre-Ramp Test
New Speed
Post-Ramp Test
Average set speed, rpm 8,850 431 8,850 470
Change in speed pre- to
post-test, rpm
N/A Absolute speed change:
424 211
Speed change in 17/28
tests: 61%
Increased speed: 8 tests
Mean increase speed
change: 450 177
Decreased speed: 9 tests
Mean decrease speed
change: 400 245
No speed change: 11 tests
LVEDD, cm, mean  SD 5.7 1.2 5.7 1.2
Blood pressure (MAP),
mm Hg, mean  SD
85.3 9.7 86.1 11.3
Frequency of aortic
valve opening
Closed: 13
Open intermittently: 3
Open every beat: 6
Excluded for AV
repair/closure at
HMII implant: 6
Closed: 9
Open intermittently: 10
Open every beat: 3
Excluded for AV
repair/closure at HMII
implant: 6HMII  HeartMate II; MAP  mean arterial pressure; other abbreviations as in Tables 1 and 2.Each patient’s LVEDD, PI, and power were plotted against
device speed, ranging in value from 8,000 to 12,000 RPM in
400-rpm increments. The slopes for the lines were gener-
ated by fitting a linear function to each of the respective
parameters using Excel 2007 software. The fit of the linear
model was assessed using a correlation between LVEDD,
PI, and power slopes and ramp speed.
Results
During the study period, 39 HeartMate II patients had a
total of 52 ramp tests.
Demographics for the 39 patients are shown in Table 2. The
mean age was 57 14 years, 85% were men, 51% had dilated
cardiomyopathy, 36% had diabetes mellitus, and 33% had a
history of hypertension. Nine patients (23%) had undergone
mitral valve repair, 8 (21%) AV repair, 1 (3%) AV closure, 4
(10%) tricuspid valve repair, and 1 (3%) patent foramen ovale
closure at the time of HeartMate II surgical implantation.
Speed optimization. Twenty-eight ramp tests were per-
formed for speed optimization. Device speed was changed
in 17 (61%) of these tests, with a mean absolute value speed
adjustment of 424  211 rpm to achieve optimal LVEDD,
AV opening, and MR as described previously.
Eight tests resulted in increased speeds for patients to
8) Versusatients (n  8) Versus
39)
No Thrombosis
Patients
(n  29) p Value
All Patients
(n  39*)
59 14 0.47 57 14
26 (90) 0.10 33 (85)
3 (12) AA, 22 (88) other 1.0 6 (15) AA, 33 (85) other
12 (48) 0.70 20 (51)
7 (28) 1.0 13 (33)
7 (28) 0.66 14 (36)
14 (56) 0.70 21 (54)
1.1 0.2 0.06
7 (28) 0.65 9 (23)
7 (28) 0.16 8 (21)
2 (8) 1.0 4 (10)
— 0.24 1 (3)
0.29 0.11 0.001 N/A
0.46 0.20 0.001 N/A
0.62 0.17 0.03 N/A
9,124 1,222 0.001
454 263 0.001 N/A
N/A N/A N/A
N/A N/A N/A
148 89 0.6 N/A
stable and being followed on a maximally intensified anticoagulation regimen are included in the
ient chart.
tricular assist device; N/A  not available; PFO  patent foramen ovale; other abbreviations as in(n sis P
n 
who is
sis patallow for improved decompression of the LVEDD and a
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speed change was 450  177 rpm. Nine tests resulted in
decreased speeds for patients to allow for at least intermit-
tent opening of the AV and to prevent leftward interven-
tricular septum deviation; the mean decreased speed change
was 400  245 rpm. In 11 tests, the speed was not
changed, and the programmed clinical speed was therefore
validated as the optimal speed. The speed optimization
results are summarized in Table 3.
The AVs in 6 of the 28 patients who underwent speed
Figure 4 Histograms of LVEDD, LDH, AV Closure Speeds, PI, an
(A) LVEDD histogram; (B) LDH histogram; (C) PI histogram; (D) speed AV closer;optimization tests were repaired and/or closed at the time ofHeartMate II surgical implantation, and these patients were
excluded from the AV optimization analysis. In the remain-
ing 22 patients, AV opening occurred in 9 patients (41%)
before and 13 patients (59%) after speed optimization. The
AV of the remaining 9 patients did not open at the lowest
pump speed that maintained adequate blood pressure with
no more than mild MR.
Suspected device thrombosis. Ramp tests were performed
in 17 patients for suspected device thrombosis. In 10
patients, the LVEDD changed only minimally with in-
wer Slopes
wer. LDH  lactate dehydrogenase; other abbreviations as in Figure 3.
Continued on next page.d Po
(E) pocreasing speeds (Fig. 3B), whereas it changed more substan-
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October 30, 2012:1764–75 The LVAD Ramp Studytially in the remaining 7 patients (Fig. 3A). Because of
heightened concern over device thrombosis based on this
finding, these 10 patients had their anticoagulation regimen
maximally intensified and were observed for worsening
hemolysis and/or evidence of end-organ dysfunction. The
latter occurred in 9 of the 10 patients, and they underwent
device exchange (n  7), device explantation (n  1), or
rgent transplantation (n  1). For these 9 patients, the
ean time to surgery after the ramp test was 9.0 9.0 days.
ne of the 10 patients remains stable on intensified
nticoagulation.
Devices in all 9 patients were examined after explanta-
ion, and thrombus was found in 8. One patient did not
ave a thrombus, but instead had a grossly disconnected
end relief, which was functioning as a major obstruction to
ow at the time of explantation. All patients who underwent
evice exchange or heart transplantation are alive without
aving experienced permanent end-organ damage. For the 8
atients with confirmed device thrombosis, the mean age was
3  20 years, 62% were males, 50% had dilated cardiomy-
pathy, and 25% were African American (Table 2). The 7
atients whose ramp test demonstrated significant changes
n LVEDD with increasing pump speed were monitored
hile on their original anticoagulation regimens. End-organ
ysfunction developed in none of them, and none experi-
Figure 4 Continuednced thromboembolic events. camp study results. LVEDD SLOPE. The LVEDD slope
eflects a reduction in left ventricular size throughout the ramp
tudy; thus, LVEDD slope is usually negative and the larger
he absolute value of the slope is, the steeper the slope. The
ean LVEDD slope was0.08 0.04 in confirmed device
hrombosis patients, and 0.29  0.11 in the remaining
patients (p  0.001). A histogram of the LVEDD slopes is
shown in Figure 4A. All patients with confirmed device
thrombosis or disconnected outflow bend relief and none of
the remaining patients had an LVEDD slope 0.16.
Thus, an LVEDD slope of 0.16 was diagnostic of flow
obstruction, usually due to device thrombosis, but in 1 case,
due to outflow bend relief disconnect.
PI SLOPE. The mean PI slope was0.16 0.04 in confirmed
evice thrombosis patients, and 0.46  0.20 in the remain-
ng patients (p  0.001). All patients (100%) with confirmed
evice thrombosis and a recorded PI had a PI slope in the
ower quartile (0.28), whereas only 5 patients (17.2%) with
ormal device function had a PI slope in the lower quartile. A
istogram of the PI slopes is shown in Figure 4C.
peed for complete closure of the AV. The mean speed at
hich the AV closed was 9,124 1,222 rpm in the patients
ithout confirmed thrombosis and 11,100  1,146 rpm in
hose with confirmed thrombosis. The histograms of AV
losure speed (Fig. 4D) show that the AVs of confirmed clot
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rest of the patient cohort without a clot.
Power slope. The mean power slope was 0.74  0.15 in
onfirmed device thrombosis patients, and 0.62  0.17 in
he remaining patients (p  0.03). A histogram of the
ower slopes is shown in Figure 4E.
Of 52 tests, the speed was increased to 12,000 rpm in 15
ests without meeting the safety endpoints outlined previ-
usly. The ramp test was terminated before reaching 12,000
pm in 37 patients; the mean speed at termination of the test
n these patients was 10,573  620 rpm. There was a total
f 22 suction events during the ramp tests. The mean speed
t which there was a suction event was 10,991  856 rpm.
here were no adverse events associated with any ramp
ests. None of the tests resulted in sustained ventricular
achyarrhythmias. No suction events occurred in the cohort
f patients with confirmed device thrombosis.
Ramp test results for 1 normal patient and 1 patient with
evice thrombosis are presented in Figures 3A and 3B,
espectively. A flat LVEDD slope, an only slightly negative
I slope, and a dramatically high-power slope characterize a
amp test suggestive of device thrombosis. A device throm-
osis visualized in the device impeller on explantation of the
evice is shown in Figure 5.
actate dehydrogenase. LDH levels were elevated in all
atients with confirmed device thrombosis with a mean
DH level of 1,737  684 IU/l. In addition, all had a
aptoglobin 7 and the mean plasma free hemoglobin was
levated at 19.1 14.0 mg/dl. Two patients had an elevated
DH level and signs of hemolysis but with the LVEDD
lope 0.16 threshold. These 2 patients were subse-
uently followed for 287 and 105 days, respectively, without
igns of left-sided heart failure or any systemic emboliza-
ion, and their devices were found to be without thrombus
hen explanted. A histogram of the LDH values is shown
n Figure 4B. LDH levels were much higher in thrombosis
atients compared with the remainder of patients with a
ean LDH level of 454  263 IU/l. Receiver-operating
Figure 5 Confirmed Device Thrombosis on Explanted Deviceharacteristic curve analysis for LDH as an indicator ofhrombosis found that an LDH level 1,103 IU/l (5 times
he upper limit of normal) has a sensitivity of 100% and a
pecificity of 92.5% (Fig. 6).
iscussion
n this study, we devised a unique, standardized clinical
amp test protocol to be routinely performed at the time of
ospital discharge for speed optimization or if device mal-
unction is suspected. We developed a standardized meth-
dology to analyze the ramp test results using the slopes
change in x/y on a graph) of the LVEDD, PI, and power
ombined with clinical parameters, such as LDH level. Our
rincipal findings are as follows. First, the performance of a
tandardized ramp test was both safe and feasible in patients
ith CF-LVADs. Second, speed changes were made in
1% of patients when the test was performed for speed
ptimization. Third, the test proved to be highly sensitive
nd specific in the detection of obstruction to flow, namely,
evice thrombosis when used in conjunction with LDH
evel.
Figure 6 ROC Curve Analysis of LDH as
an Indicator of Device Thrombosis
The specificity and sensitivity values for LDH as an indicator for thrombosis
were identified from the ROC curve. An LDH value 750 IU/l has a specificity
of 85% and should trigger further evaluation for device thrombosis diagnosis.
The optimal results were achieved with an LDH cutoff of 1,103 IU/l. The blue
region of the graph represents a 95% confidence interval (CI) for the ROC curve
using the bootstrap method in the pROC package (11) in R version 2.15.0.
AUC  area under the curve; LDH  lactate dehydrogenase; ROC  receiver-
operating characteristic.
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October 30, 2012:1764–75 The LVAD Ramp StudyEchocardiography has rapidly assumed a central role in
understanding the complex patient–device interface. Topil-
sky et al. (6) reviewed the use of echocardiography for speed
adjustment and elegantly characterized the relationship
between LVEDD, optimal septum position, and severity of
MR for optimal device support benefit. However, in their
study, repeated echocardiographic imaging needed to be
performed to achieve the stated goals. Slaughter et al. (12)
recommended the performance of ramp tests on every
patient after device implantation; these authors advised that
tests be done in the operating room at the end of device
implantation surgery with transthoracic echocardiography
and hemodynamic monitoring. There is no doubt that this
initial ramp test is important in the early postoperative care
of patients with LVADs; however, immediate postoperative
conditions will almost certainly be different from the con-
ditions in which stable LVAD patients are discharged from
the hospital. It is reasonable to assume that after optimiza-
tion of volume status and weaning off both inotropic and
vasoactive medications (12) before discharge, the relation-
ship between device speed and optimal hemodynamics will
be different from what it had been in the immediate
postoperative period. Furthermore, the immediate postop-
erative goals for the device–patient interface may be differ-
ent from those of long-term care. For example, in the initial
phase, speed adjustment to allow for AV opening is not
crucial to patient care. However, during the long-term
phase of device treatment, there is a clear association of the
AV remaining closed and the development of AI in patients
supported by continuous-flow pumps (7).
Although advocated in the care of CF-LVAD patients,
currently, no standardized clinical protocol for performance
of a ramp test exists. Consequently, each medical center uses
its own discretion for performing speed adjustments and
diagnosing device malfunctions. Here we present the Co-
lumbia Ramp Study, which enumerates a standardized
echocardiographically guided assessment of the relationship
between the device and the patient, including study indica-
tions, contraindications, speed change intervals, echocardio-
graphic parameters to measure, and a novel methodology for
analyzing the data obtained with mathematical inference.
With a single study, the clinician gains an accurate
understanding of the optimal device settings to preserve left
ventricular geometry, reduce MR severity, and allow the AV
to open intermittently. Routine application of this test
allows for an overall characterization of the interface be-
tween the patient’s native heart and the device. Importantly,
each patient’s baseline ramp test results also serve as an
important reference with which to compare future test
results, which may be done in the setting of suspected device
thrombosis or device malfunction, much like a B-type
natriuretic peptide level drawn during euvolemia.
Perhaps even more important than its use for speed
optimization is the test’s ability to aid in the diagnosis of
pump thrombosis. Previous literature on CF-LVADs re-
ported that the frequency of device thrombosis is in therange of 2% in the bridge-to-transplantation population (2)
and 4% in the destination therapy population (1). Of note,
a strict definition for device thrombosis was applied in the
clinical trials:
“Any obstructive thrombus in the device or its conduits
associated with clinical symptoms of impaired pump per-
formance (decreased pump flow, need to increase pump
speed, increased power, hemolysis) or the need for throm-
bolytic or surgical intervention. In addition, pumps will be
analyzed at Thoratec. Any severe thrombus scored as a level
3 thrombus (50% obstruction) will be captured as an
event” (1).
The true incidence of clinically relevant device thrombosis
may be higher. The problem of device thrombosis will surely
remain an important one as newer continuous-flow ventric-
ular assist devices such as the HeartWare device (Heart-
Ware International) are introduced into clinical practice.
Risk factors for device thrombosis have been reported and
include less aggressive anticoagulation, infection, and hy-
percoagulability syndromes (i.e., systemic lupus erythema-
tosus). One barrier in the treatment of patients with device
thrombosis stems from the difficulty in making this diag-
nosis before catastrophic thromboembolic events. Cur-
rently, suspicion of thrombosis arises when there are signs of
hemolysis (elevated LDH, high plasma free hemoglobin,
and low haptoglobin levels), transient increases in device
power 14 days post-implantation, or recurrence of con-
gestive heart failure (1). However, these criteria lack both
sensitivity and specificity for the diagnosis of device throm-
bosis. Regular echocardiography typically fails to diagnose
the majority of device thromboses (13,14). CT scan with
contrast media has been proposed as a diagnostic option for
inflow and outflow cannulas thrombosis (15,16), but is a
severely limited approach because thrombus within the
device cannot be detected.
In the current study, we observed that the ramp test can
identify a perturbation of the relationship between the
patient’s native heart and the device. We demonstrated that
LVEDD slope correlates with device thrombosis and/or
severe outflow obstruction due to a disconnected bend relief.
This finding is explained by the fact that the impediment to
flow caused by device thrombosis leads to an uncoupling of
the relationship between the device speed and LVEDD. In
other words, blunted reductions in LVEDD in response to
an increase in pump speed indicate an obstruction to flow
through the device. Not surprisingly, LVEDD slopes were the
most accurate measure in the diagnosis of thrombosis. The
combination of clinical suspicion for thrombosis based on heart
failure symptoms, LDH levels, LVEDD, PI, and power slopes
led us to intensify anticoagulation regimens and/or perform
device exchange in 8 patients, 7 (88%) of whom were found to
have device thrombosis, with the eighth patient having an
obstruction to flow due to a gross bend relief disconnect.
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tive analysis of a relatively small cohort of patients. Second,
our method for definitive diagnosis of pump thrombosis was
to send suspected thrombosis pumps to Thoratec Corpora-
tion after explantation at Columbia University Medical
Center for further inspection of the pump housing and final
validation of device clot. This may introduce selection bias.
Our current practice is to send all explanted pumps, includ-
ing both “normal” and malfunctioning pumps to the man-
ufacturer for disassembly and inspection. Third, the ramp
test protocol is time-consuming and cumbersome in that it
requires strict adherence to the 2-min time interval between
speed designations. This ramp test protocol may be able to
be abbreviated once a larger dataset is reviewed. We
designed a protocol to be used with the HeartWare device,
and preliminary results are indicative of the ramp test being
a beneficial tool for speed adjustment and device malfunc-
tion diagnosis.
Figure 7 Suspected Device Malfunction Algorithm
Suggested management algorithm for patients with suspected device thrombosis.Further follow-up is needed on the patients who under-
went the ramp test for speed optimization for outcome
evaluation, the development of AI, and frequency of device-
related complications.
Recommendation. Based on our experience at Columbia
University Medical Center, we developed a working algorithm
to facilitate the diagnosis of device malfunction (Fig. 7).
Conclusions
Ramp tests performed to monitor appropriateness of CF-
LVAD programmed settings very frequently led to changes
in device speed and, therefore, should be done routinely in
CF-LVAD recipients. Ramp tests allowed device malfunc-
tion detection in the setting of suspected device thrombosis,
and, pending validation in larger studies, they may be used
to monitor the effects of therapeutic interventions and to
determine the need for surgical intervention.
basic metabolic panel; Pt  patient; other abbreviations as in Figures 1 and 3.BMP 
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